These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12177396)

  • 1. Disease modifying therapies in multiple sclerosis.
    Fox RJ; Fisher E; Rudick R
    Neurology; 2002 Aug; 59(3):471-2; author reply 472-3. PubMed ID: 12177396
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a.
    Tola MR; Caniatti LM; Gragnaniello D; Russo M; Stabellini N; Granieri E
    J Neurol; 2003 Jun; 250(6):768-9. PubMed ID: 12862038
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid onset of ulcerative colitis after treatment with interferon β1a in a patient with multiple sclerosis.
    Tuna Y; Başar O; Dikici H; Köklü S
    J Crohns Colitis; 2011 Feb; 5(1):75-6. PubMed ID: 21272812
    [No Abstract]   [Full Text] [Related]  

  • 4. Rebif offers another option for treating multiple sclerosis.
    Ryan M
    J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients.
    Morra VB; Coppola G; Orefice G; De Michele G; Vacca G; Filla A; Bonavita V
    Neurology; 2004 Mar; 62(5):829-30. PubMed ID: 15007146
    [No Abstract]   [Full Text] [Related]  

  • 6. Meningioma growth during interferon beta-1A treatment for multiple sclerosis.
    Gama HP; Rocha AJ; Silva CJ; Mendes MF; Veiga JC; Lancellotti CL; Andrade VP; Tilbery CP
    Arq Neuropsiquiatr; 2008 Jun; 66(2B):402-4. PubMed ID: 18641881
    [No Abstract]   [Full Text] [Related]  

  • 7. A nexus between lipids and multiple sclerosis?
    Zorzon M
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1181. PubMed ID: 23595948
    [No Abstract]   [Full Text] [Related]  

  • 8. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson.
    Alsalameh S; Manger B; Kern P; Kalden J
    Arthritis Rheum; 1998 Apr; 41(4):754. PubMed ID: 9550494
    [No Abstract]   [Full Text] [Related]  

  • 9. Shortcomings in pharmacy benefit forecasting--interferon beta products.
    Rich SJ; Meyer C
    J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461
    [No Abstract]   [Full Text] [Related]  

  • 10. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute hepatitis secondary to interferon beta-1a in multiple sclerosis.
    Christopher V; Scolding N; Przemioslo RT
    J Neurol; 2005 Jul; 252(7):855-6. PubMed ID: 15742101
    [No Abstract]   [Full Text] [Related]  

  • 12. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial: Licensing and Use of New Therapies in MS: Where Are We Going?
    Hurwitz B
    Int MS J; 2005 Aug; 12(2):39-41. PubMed ID: 16417813
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of multiple sclerosis with interferon beta-1 b.
    Abdul-Ahad A; Shah S; Galazka A
    Neurology; 1997 Aug; 49(2):641-2. PubMed ID: 9270626
    [No Abstract]   [Full Text] [Related]  

  • 16. Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies--an update.
    Donoghue S; Greenlees C
    Expert Opin Investig Drugs; 2000 Jan; 9(1):167-71. PubMed ID: 11060669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.
    Barnes CJ; Caon C; Foley JF; Friedman M; Menzin J; Nair KV; Nichols C; Olvey EL; Owens GM; Pill MW; Skrepnek GH; White LA; Zerkowski K
    J Manag Care Pharm; 2013; 19(1 Suppl A):S1-53. PubMed ID: 23383730
    [No Abstract]   [Full Text] [Related]  

  • 18. Introduction.
    Owens GM
    J Manag Care Pharm; 2013; 19(1 Suppl A):S3. PubMed ID: 23383727
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of interferon beta 1b for multiple sclerosis. Manufacturer defends the drug.
    Longthorne PN
    BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939141
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated.
    Cardy P
    BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939142
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.